Cipher’s leadership has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products. Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.
Stephen Lemieux, who has more than 13 years of public company experience, most recently served as Vice President and Chief Financial Officer of Nuvo Pharmaceuticals (TSX:NRI) ("Nuvo"), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. He was appointed Chief Financial Officer of Nuvo in January 2012. In his role, Mr. Lemieux was responsible for all of Nuvo's financial operations as well as information technology, manufacturing, human resources and planning. Mr. Lemieux's transactional experience includes licensing and asset sales, debt and equity financing, acquisitions, corporate reorganizations and plans of arrangement.
Prior to joining Nuvo in 2007, Mr. Lemieux was the Corporate Controller at Martinrea International Inc., a Tier One automotive supplier. Prior to joining Martinrea, Mr. Lemieux was the Assistant Controller at Magna Powertrain (formerly Tesma International Inc.) and had previously held the position of Manager, Global Financial Reporting. Tesma was a Tier One automotive supplier and a public company listed on the TSX and NASDAQ. Prior to joining Tesma, Mr. Lemieux worked for Ernst & Young performing audit, restructuring and accounting work for its clients. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting from the University of Toronto.
Ralph brings more than 30 years of dermatologic sales, marketing and management experience in both the US and Canada. Prior to joining Cipher, he was Executive Director of Taro Pharma, the branded dermatology division of Taro Pharmaceuticals. Previously, he was Vice President, Sales for Triax Pharmaceuticals, and held numerous Sr. Level positions during a 14 year career at Medicis, The Dermatology Company, including Sr. Vice President, Sales; President, Medicis Canada; and General Manager for their pediatric and orphan drug subsidiaries. Ralph also founded and directed the consulting firm Ridgeback Associates, providing companies with insight and direction toward specific and measurable sales, marketing, and business development objectives within the pharmaceutical sector.
Joan Chypyha has more than 25 years of experience in the pharmaceutical industry with an emphasis on marketing, sales and business development. Previously Ms. Chypyha was Chief Development Officer of Rhei Pharmaceuticals Ltd.; Vice President, Corporate Development at Barrier Therapeutics Inc.; General Manager of Barrier Therapeutics Canada Inc.; and Founder of Alto Pharmaceuticals Ltd. She also spent 16 years with Hoffman-La Roche in several progressively senior positions, including Business Unit Director, Dialysis and PPN, and Business Unit Director, Dermatology. In this role, Ms. Chypyha was responsible for the management of a specialty sales force that represented Accutane, among other brands. She received her Bachelor of Science from University of Toronto and completed an Executive MBA from Queen’s University.
Linda Angaritis has more than 30 years of experience in the pharmaceutical industry both abroad and in Canada. She has held senior-level positions in multinational brand companies, as well as generics, covering all dosage forms from solid oral dose through to biologics and vaccines. She has extensive experience in manufacturing, regulatory and quality, with a focus on continuous improvement and remediation. Previous positions include Site Quality Head positions at Apotex and Eli Lilly, and Director of Quality Systems and Continuous Improvement at Sanofi Pasteur. Ms. Angaritis received her Pharmacy degree from Rhodes University in South Africa and is a Canadian-registered pharmacist, having completed her PEBC exams in Canada.
Lynne Bulger brings 27 years of experience in the pharmaceutical industry, conducting clinical research trials in phase I-IV and providing strategic medical marketing support in dermatology, rheumatology, osteoporosis and CNS. She has lead drug development programs for topical and systemic therapies in acne, psoriasis, onychomycosis, atopic dermatitis, ichthyosis, photodamage, blistering diseases, seborrheic dermatitis and actinic keratosis. Ms. Bulger developed the first acne mentorship programs in Canada, spearheaded the Canadian Acne Observational Database initiative, and worked with dermatologists to develop improved study outcome measurements in acne, photodamage and atopic dermatitis. She has a special interest in retinoids because of her role in the development and medical management of acitretin and isotretinoin. Previously, Ms. Bulger was Director, Medical Affairs at GSK; Director, Medical Affairs at Stiefel Laboratories; Director, Medical and Regulatory Affairs at Barrier Therapeutics; and Director, Medical Affairs at Hoffmann-La Roche.
Peter Weiler is a seasoned 15-year veteran of the pharmaceutical industry. He has been with Cipher Pharmaceuticals since 2008 and has led the Business Development team since 2011. As Vice President of Business Development, Mr. Weiler has overall responsibility for building Cipher’s dermatology product portfolio, achieving Cipher’s vision for growth through M&A and maximizing the value of Cipher’s legacy assets through development of commercial partnerships in markets outside North America. Prior to Cipher, he spent a number of years in the private equity market, most recently as Senior Director of Investment Analysis with DRI Capital, a highly successful royalty monetization fund specializing in the acquisition of royalty streams from prescription medications. He started his pharmaceutical career by joining the finance team at Eli Lilly Canada before transitioning into roles in market research, first with the oncology group and later with Lilly’s cornerstone diabetes franchise. Mr. Weiler holds an MSc in Biology from the University of Western Ontario and an MBA from the Ivey School of Business at UWO.
Mark Spina has more than 22 years of experience with large, multinational corporations in various finance roles. He joined Cipher’s leadership team in April 2015 through the acquisition of Innocutis Holdings, LLC where he was CFO. For seven years prior, Mr. Spina served as Director of Plant Controlling, Finance & Accounting at Robert Bosch LLC for one of its multi-billion dollar business. Prior to 2007, Mr. Spina spent 14 years with Abbott Laboratories in a number of corporate finance roles within medical, pediatric, consumer and device businesses supporting sales, marketing, operations and research and development. Also while at Abbott Laboratories, Mr. Spina served as Head of Plant IT and Plant Materials Control Manager where he was responsible for the global distribution of plant products. Mr. Spina received his Bachelor of Science degrees in Accounting and Management (with a concentration in Finance) from Purdue University. Currently, he is a Certified Public Accountant registered with the Illinois CPA Society and a member of the American Institute of Certified Public Accountants. His community service roles include Treasurer of the Board of Directors for Central Virginia Federal Credit Union and Board Member for Lynchburg Junior Achievement.
Chuck Jenkins has more than 15 years of progressive experience in pharmaceutical sales, sales management, marketing and business development. He joined Cipher's leadership team in April 2014 through the acquisition of Innocutis Holdings, LLC. Previously Mr. Jenkins was the co-founder of Innocutis Medical, LLC and held numerous commercial positions at both Ferndale Laboratories and Medicis Pharmaceuticals. As Senior Brand Manager in Dermatology Marketing, Mr. Jenkins was responsible for all commercial efforts of SOLODYN®, which accounted for 55% of the company’s revenue. He grew SOLODYN® from a plateau of ~$420M to over $750M in less than two short years. Under Mr. Jenkins’ management, SOLODYN® became the #1 most prescribed branded drug in dermatology.
Mr. Jenkins received his Bachelors of Science in Business Administration degree from The University of South Carolina.
Daniel Ward, MD, is a board-certified dermatologist and a fellow of the American Academy of Dermatology. He joined Cipher through the acquisition of Innocutis Holdings, LLC in April 2014 where he was also Medical Director. Dr. Ward has worked in both academic and private practice settings, and was Clinical Assistant Professor at the Medical University of South Carolina from 2006 to 2012. He has a Bachelor of Science degree in Biology with a cognate in chemistry from the University of South Carolina (Honors College), and attended medical school at the University of South Carolina School of Medicine, where he was elected to Alpha Omega Alpha. Dr. Ward completed an internship in Internal Medicine and a residency in Dermatology at the Medical University of South Carolina in Charleston, where he served as Chief Resident during his final year.